Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
damoctocog alfa pegol + octocog alfa
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This drug entry refers to the combination or co-administration of damoctocog alfa pegol (Jivi) and octocog alfa (Kogenate FS), as evaluated in clinical trial settings for hemophilia A. Damoctocog alfa pegol is a site-specifically PEGylated recombinant factor VIII (rFVIII) replacement therapy developed by Bayer, featuring a 60 kDa branched PEG molecule that significantly extends its half-life in the bloodstream. Octocog alfa is a standard recombinant factor VIII. Both components function by replacing the missing or deficient clotting factor VIII in patients with hemophilia A, thereby restoring the intrinsic pathway of the coagulation cascade and enabling effective blood clot formation. The combination was specifically studied in Phase 1 trials to compare the pharmacokinetic and safety profiles of the long-acting PEGylated factor VIII against the standard recombinant factor VIII in previously treated patients.
- Brand names
- JiviKogenate FS
- Other names
- BAY94-9027 + recombinant factor VIII-Bayer-hemophilia Adamoctocog alfa pegoloctocog alfarecombinant factor VIII
02
Targets
BB-031 (Von Willebrand factor)F8 (Coagulation Factor VIIIa)
Beyond the preview
Go deeper on damoctocog alfa pegol + octocog alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on damoctocog alfa pegol + octocog alfa.